Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Early phase data has suggested that Eli Lilly and Sankyo's co-developed investigational anti-clotting agent, prasugrel, demonstrated greater and more reliable blood thinning effect compared to Bristol-Myers Squibb and Sanofi-Aventis' Plavix, even in patients with increased platelet reactivity.
Subscribe to our email newsletter
In a phase Ib study, greater than 90% of prasugrel-treated patients achieved greater than 20% inhibition of platelet aggregation, compared with less than 50% of Plavix treated patients.
The study showed that even patients with more reactive platelets at baseline, a population whose platelets may be less affected or unaffected by current thienopyridine therapies, have higher and more consistent inhibition of platelet aggregation with prasugrel than with Plavix.
“Certain patients have more reactive platelets that are less affected or unaffected by current thienopyridines, so it is very encouraging to see in this study how well the platelets of those who were dosed with prasugrel responded, regardless of baseline platelet reactivity,” said Dr Joseph Jakubowski, research fellow, Eli Lilly and Company.